CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation

Harvard spin-off CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality.

$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH
Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company's technology platform, strengthening the team, and advancing the mitochondria's GMP manufacturing

Zurich/Switzerland and Houston/USA, February 6^th, 2023: cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an approach developed at Harvard Medical School, closes a $5.5 Million financing to get Series A-ready by the end of 2023.

Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are commonly known as the powerhouses of the cell, generating most of its needed energy and operating as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, over heart attacks and strokes, to age-related degeneration. "Whilst Mitochondria have been known as disease targets for a long time, treating them has proven challenging", notes Dr. James McCully, a co-founder of cellvie and inventor of TMT. That's why he turned to transplanting viable mitochondria to reinvigorate the cell energy metabolism, which was impaired due to ischemia, an undersupply of oxygen which arises in medical conditions such as heart attacks or stroke and during organ transplantation.

"Given the insights gained and treatment successes shown by my scientific co-founders, we have always viewed mitochondria as a potential new category of medicines," says Dr. Alexander Schueller, co-founder and CEO of cellvie. "To realize the modality's potential, we have therefore focused our efforts over the past two years on scalable productization – developing an allogeneic off-the-shelf product – and research on new therapeutic applications of mitochondria – such as in gene therapy delivery and aging related degeneration." With this additional funding, cellvie intends to accelerate and expand the scientific development of its mitochondria platform and to further strengthen the organizational foundations in preparation for the Series A. Dr. Schueller notes that "while many companies need to conserve cash and slow down shortly before raising their next round of funding, we are now in the position to speed up and form an even stronger basis to immediately and efficiently put the Series A funding to work."

Taiho Ventures LLC joins Kizoo Technology Capital as one of cellvie's primary investors and will take a board seat to help the company realize its ambitions. "We have recognized the tremendous potential in the therapeutic use of mitochondria, particularly in the fight against cancer, and we believe that cellvie is very well positioned to become a leader in this emerging field," says Sakae Asanuma, President and CEO at Taiho Ventures LLC. Kizoo is also a significant co-investor in this round, having gained ever more confidence in the technology and the potential of the team since leading the company's seed round in 2020. Frank Schueler, Managing Director at Kizoo and member of the board at cellvie says: "The team has done a tremendous job in advancing our understanding and pushing the boundaries of mitochondria-based therapies. So it was only natural for us to continue to support cellvie as one of our key startups."

About cellvie: www.cellvie.bio.

About Taiho Ventures: https://taihoventures.com.

About KIZOO Technology Capital: www.kizoo.com and www.forever-healthy.org

Contact:Alexander Schueller, CEO
ph: +41-44 591 89 21
email:
contact@cellvie.bio

Back to news